Page 1722 - Hematology_ Basic Principles and Practice ( PDFDrive )

1530.e2 Part VII Hematologic Malignancies

38. Pulsipher MA, Chitphakdithai P, Logan BR, et al: Acute toxicities of 59. To LB, Levesque J-P, Herbert KE: How I treat patients who mobilize
unrelated bone marrow versus peripheral blood stem cell donation: hematopoietic stem cells poorly. Blood 118(17):4530–4540, 2011.
results of a prospective trial from the National Marrow Donor Program. 60. Dührsen U, Villeval J-L, Boyd J, et al: Effects of recombinant human
Blood 121:197–206, 2013. granulocyte colony-stimulating factor on hematopoietic progenitor cells
39. Kao GS, Kim HT, Daley H, et al: Validation of short-term handling in cancer patients. Blood 72(6):2074–2081, 1988.
and storage conditions for marrow and peripheral blood stem cell 61. Socinski MA, Cannistra SA, Elias A, et al: Granulocyte-macrophage
products. Transfusion 51(1):137–147, 2011. colony stimulating factor expands the circulating haemopoietic
40. Bosi A, Bartolozzi B: Safety of bone marrow stem cell donation: a progenitor cell compartment in man. Lancet 1(8596):1194–1198,
review. Transplant Proc 42(6):2192–2194, 2010. 1988.
41. Halter J, Kodera Y, Ispizua A, et al: Severe events in donors after allo- 62. Welte K, Gabrilove J, Bronchud MH, et al: Filgrastim (r-metHuG-
geneic hematopoietic stem cell donation. Haematologica 94(1):94–101, CSF): the first 10 years. Blood 88(6):1907–1929, 1996.
2009. 63. Watts MJ, Addison I, Long SG, et al: Crossover study of the hae-
42. Anthias C, Ethell ME, Potter MN, et al: The impact of improved matological effects and pharmacokinetics of glycosylated and non-
JACIE standards on the care of related BM and PBSC donors. Bone glycosylated G-CSF in healthy volunteers. Br J Haematol 98(2):474–479,
Marrow Transplant 50:244–247, 2015. 1997.
43. Solves P, Mirabet V, Perales A, et al: Banking strategies for improving 64. De Arriba F, Lozano ML, Ortuño F, et al: Prospective randomized
the hematopoietic stem cell content of umbilical cord blood units for study comparing the efficacy of bioequivalent doses of glycosylated and
transplantation. Curr Stem Cell Res Ther 3(2):79–84, 2008. nonglycosylated rG-CSF for mobilizing peripheral blood progenitor
44. Barker JN, Byam C, Scaradavou A: How I treat: the selection and cells. Br J Haematol 96(2):418–420, 1997.
acquisition of unrelated cord blood grafts. Blood 117(8):2332–2339, 65. Weise M, Bielsky MC, De Smet K, et al: Biosimilars: what clinicians
2011. should know. Blood 120:5111–5117, 2012.
45. Cairo MS, Wagner EL, Fraser J, et al: Characterization of banked 66. Bonig H, Becker PS, Schwebig A, et al: Biosimilar granulocyte-colony-
umbilical cord blood hematopoietic progenitor cells and lymphocyte stimulating factor for healthy donor stem cell mobilization: need we be
subsets and correlation with ethnicity, birth weight, sex, and type afraid? Transfusion 55:430–439, 2015.
of delivery: a Cord Blood Transplantation (COBLT) Study report. 67. Shaw BE, Confer DL, Hwang WY, et al: Concerns about the use of
Transfusion 45(6):856–866, 2005. biosimilar granulocyte colony-stimulating factors for the mobilization
46. Solves P, Marabet V, Roig R: Volume reduction in routine cord blood of stem cells in normal donors: position of the World Marrow Donor
banking. Curr Stem Cell Res Ther 5(4):362–366, 2010. Association. Haematologica 96:942–947, 2011.
47. Klein MA, Kadidlo D, McCullough H, et al: Microbial contamination 68. Weise M, Kurki P, Wolff-Holz E, et al: Biosimilars: the science of
of hematopoietic stem cell products: incidence and clinical sequelae. extrapolation. Blood 124:3191–3196, 2014.
Biol Blood Marrow Transplant 12(11):1142–1149, 2006. 69. Elayan MM, Horowitz JG, Magraner JM, et al: Tbo-filgrastim versus
48. Brecher G, Cronkite EP: Postradiation parabiosis and survival in rats. filgrastim during mobilization and neutrophil engraftment for autolo-
Proc Soc Exp Biol Med 77(2):292–294, 1951. gous stem cell transplantation. Biol Blood Marrow Transplant 2015.
49. To LB, Roberts MM, Haylock DN, et al: Comparison of haemato- [Epub ahead of print].
logical recovery times and supportive care requirements of autologous 70. Lane TA, Law P, Maruyama M, et al: Harvesting and enrichment of
recovery phase peripheral blood stem cell transplants, autologous bone hematopoietic progenitor cells mobilized into the peripheral blood of
marrow transplants and allogeneic bone marrow transplants. Bone normal donors by granulocyte-macrophage colony-stimulating factor
Marrow Transplant 9(4):277–284, 1992. (GM-CSF) or G-CSF: potential role in allogeneic marrow transplanta-
50. Fermand J-P, Levy Y, Gerota J, et al: Treatment of aggressive mul- tion. Blood 85(1):275–282, 1995.
tiple myeloma by high-dose chemotherapy and total body irradiation 71. Grigg AP, Roberts AW, Raunow H, et al: Optimizing dose and schedul-
followed by blood stem cells autologous graft. Blood 73(1):20–23, ing of filgrastim (granulocyte colony-stimulating factor) for mobiliza-
1989. tion and collection of peripheral blood progenitor cells in normal
51. Juttner CA, To LB, Ho JQK, et al: Early lympho-hemopoietic recovery volunteers. Blood 86(12):4437–4445, 1995.
after autografting using peripheral blood stem cells in acute non- 72. Weaver CH, Birch R, Greco FA, et al: Mobilization and harvesting of
lymphoblastic leukemia. Transplant Proc 20(1):40–42, 1988. peripheral blood stem cells: randomized evaluations of different doses
52. Kessinger A, Armitage JO, Landmark JD, et al: Autologous peripheral of filgrastim. Br J Haematol 100(2):338–347, 1998.
hematopoietic stem cell transplantation restores hematopoietic function 73. Anderlini P, Donato M, Lauppe MJ, et al: A comparative study of once-
following marrow ablative therapy. Blood 71(3):723–727, 1988. daily versus twice-daily filgrastim administration for the mobilization
53. Nadamanee A, Sniecinski I, Schmidt GM, et al: High-dose therapy and collection of CD34 peripheral blood progenitor cells in normal
followed by autologous peripheral-blood stem-cell transplantation donors. Br J Haematol 109(4):770–772, 2000.
for patients with Hodgkin’s disease and non-Hodgkin’s lymphoma 74. Lee V, Li CK, Shing MM, et al: Single versus twice daily G-CSF dose
using unprimed and granulocyte colony-stimulating factor-mobilized for peripheral blood stem cells harvest in normal donors and children
peripheral-blood stem cells. J Clin Oncol 12(10):2176–2186, 1994. with non-malignant diseases. Bone Marrow Transplant 25(9):931–935,
54. Sheridan WP, Begley CG, To LB, et al: Phase II study of autologous fil- 2000.
grastim (G-CSF)-mobilized peripheral blood progenitor cells to restore 75. Bishop MR, Tarantolo SR, Jackson JD, et al: Allogeneic-blood stem-cell
hemopoiesis after high-dose chemotherapy for lymphoid malignancies. collection following mobilization with low-dose granulocyte colony-
Bone Marrow Transplant 14(1):105–111, 1994. stimulating factor. J Clin Oncol 15(4):1601–1607, 1997.
55. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment 76. Stroncek DF, Clay ME, Petzoldt ML, et al: Treatment of normal indi-
kinetics as a function of the CD34 content of peripheral blood viduals with granulocyte-colony stimulating factor: donor experiences
progenitor cell collections in 692 patients after the administration of and the effects on peripheral blood CD34+ cell counts and on the
myeloablative chemotherapy. Blood 86(10):3961–3969, 1995. collection of peripheral blood stem cells. Transfusion 36(7):601–610,
56. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence 1996.
collection and engraftment of autologous peripheral-blood stem cells. 77. Pulsipher MA, Chitphakdithai P, Miller JP, et al: Adverse events among
J Clin Oncol 13(10):2547–2555, 1995. 2408 unrelated donors of peripheral blood stem cells: results of a
57. Boulas PE, Frenette PS: Making sense of hematopoietic stem cell prospective trial from the National Marrow Donor Program. Blood
niches. Blood 125:2621–2629, 2015. 113(15):3604–3611, 2009.
58. Sharma M, Afrin F, Satija N, et al: Stromal-derived factor-1/CXCR4 78. Shaw BE, Confer DL, Hwang W, et al: A review of the genetic and
signaling: indispensable role in homing and engraftment of hema- long-term effects of G-CSF injections in healthy donors: a reassuring
topoietic stem cells in bone marrow. Stem Cells Dev 20(6):933–946, lack of evidence for the development of haematological malignancies.
2011. Bone Marrow Transplant 50:334–340, 2015.